Early observations and pilot data that first suggested a new direction
For decades, bronchiolitis was treated with bronchodilators and corticosteroids borrowed from asthma management, despite minimal evidence of benefit. Early small trials showed inconsistent results with albuterol and epinephrine in infants with RSV bronchiolitis. A pivotal Cochrane review in 2004 by Kellner et al. synthesized available evidence and found no meaningful improvement in hospitalization rates or clinical scores with bronchodilator use. This set the stage for a fundamental rethinking of bronchiolitis treatment.
Landmark RCTs and pivotal trials that established the evidence base
The landmark CANADIAN BRONCHIOLITIS EPINEPHRINE STEROID TRIAL (CanBEST) published in 2009 in the NEJM randomized 800 infants to epinephrine plus dexamethasone versus placebo in a factorial design. While a combination showed modest benefit, neither agent alone reduced admissions. Simultaneously, a large Cochrane update on corticosteroids by Fernandes et al. confirmed no benefit on length of stay or readmission. The AAP released its first evidence-based guideline in 2006, tentatively recommending against routine bronchodilator use, marking the beginning of formal de-implementation.
Follow-up studies, subgroup analyses, and real-world validation
The AAP published its definitive 2014 clinical practice guideline strongly recommending against routine albuterol, epinephrine, corticosteroids, chest physiotherapy, and antibiotics. Research pivoted to supportive interventions. Hypertonic saline nebulization showed promise in some trials but the large multicenter HYPER-RCT and subsequent Cochrane review showed no reduction in length of stay for ED patients. The PARIS trial by Franklin et al. in the NEJM (2018) demonstrated that high-flow nasal cannula was non-inferior to standard oxygen therapy and could be used as rescue, transforming respiratory support in bronchiolitis.
Integration into clinical practice guidelines and recommendations
The AAP 2014 guideline was a watershed moment in pediatric de-implementation, explicitly recommending against routine use of bronchodilators, epinephrine, corticosteroids, chest physiotherapy, and antibiotics. NICE updated its bronchiolitis guideline in 2021 reinforcing supportive care. The AAP issued minor updates emphasizing high-flow nasal cannula as appropriate rescue therapy. Multiple quality improvement studies demonstrated that guideline implementation reduced unnecessary interventions by 30-60% across children's hospitals.
AAP Clinical Practice Guideline: Management of Bronchiolitis
Clinicians should NOT administer albuterol, epinephrine, or systemic corticosteroids to infants with bronchiolitis. Supportive care with nasal suctioning and supplemental oxygen as needed is recommended.
NICE Guideline NG9: Bronchiolitis in Children
Do not use any of the following to treat bronchiolitis: antibiotics, hypertonic saline, adrenaline, salbutamol, montelukast, ipratropium bromide, or systemic or inhaled corticosteroids.
Now
Current standard of care and ongoing research directions
Bronchiolitis management has become a poster child for evidence-based de-implementation in pediatrics. Standard of care is supportive: nasal suctioning, hydration, and supplemental oxygen when SpO2 drops below 90-92%. High-flow nasal cannula is widely used as rescue therapy. RSV prophylaxis has evolved with nirsevimab (Beyfortus), a long-acting monoclonal antibody approved in 2023 for all infants, shifting focus toward prevention. Ongoing research examines optimal oxygen saturation targets and safe discharge criteria to further reduce unnecessary hospitalization.
Why don't bronchodilators work in bronchiolitis like they do in asthma?+
Bronchiolitis pathology involves airway edema, mucus plugging, and epithelial necrosis in small airways, not bronchospasm of larger airways. Bronchodilators target smooth muscle relaxation, which does not address the underlying viral inflammatory process in infants.
When should high-flow nasal cannula be used in bronchiolitis?+
High-flow nasal cannula (HFNC at 2 L/kg/min) is recommended as rescue therapy when standard low-flow oxygen fails to maintain adequate oxygenation. The PARIS trial showed it is safe and effective but does not need to be first-line for all hospitalized infants.
Has nirsevimab changed bronchiolitis prevention?+
Yes. Nirsevimab (Beyfortus), approved in 2023, is a long-acting monoclonal antibody given as a single dose to all infants entering their first RSV season. It provides ~75% reduction in RSV-related hospitalizations and represents a paradigm shift from treatment to prevention.
What is the evidence on hypertonic saline for bronchiolitis?+
While early smaller trials suggested benefit, large multicenter RCTs and Cochrane reviews found no reduction in length of stay for emergency department patients. Some benefit may exist for already-hospitalized infants, but routine use is not recommended by current guidelines.
